Stevens-Johnson syndrome associated with carvedilol therapy

American Journal of Cardiology

Volumn 80, Issue 5, 1997, Pages 669-670

  Kowalski, Bruce J ^a   Cody, Robert J ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; DIGOXIN; FAMOTIDINE; FUROSEMIDE; HYDRALAZINE; WARFARIN;

AGED; ARTICLE; CASE REPORT; DEFIBRILLATOR; HEART VENTRICLE ARRHYTHMIA; HUMAN; ISCHEMIC HEART DISEASE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME;

ADRENERGIC BETA-ANTAGONISTS; AGED; CARBAZOLES; HUMANS; MALE; MYOCARDIAL ISCHEMIA; PROPANOLAMINES; STEVENS-JOHNSON SYNDROME; VASODILATOR AGENTS;

EID: 0030955177     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00449-9     Document Type: Article

References (3)

1. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334:1349-1355.
2. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, Mockenhaupt M, Paoletti C, Shapiro S, Shear N, Schopf E, Kaufman DW. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333: 1600-1607.
3. Shusterman NH. Clinical Research, Development and Medical Affairs, North America, SmithKline Beecham Pharmaceuticals, November 30, 1995.